Roopa Industries Ltd

Roopa Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive price level. Despite recent share price declines and a challenging sector backdrop, the company’s improved price-to-earnings and price-to-book ratios relative to peers suggest a compelling entry point for investors willing to navigate near-term volatility.

Roopa Industries Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 07 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Roopa Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from very attractive to attractive territory. Despite a recent upgrade in valuation grades, the company’s overall market performance remains mixed, with significant divergence from benchmark indices such as the Sensex. This article analyses the evolving price attractiveness of Roopa Industries, comparing its key valuation metrics against historical averages and peer companies to provide a comprehensive investment perspective.

Roopa Industries Ltd’s shares touched a fresh 52-week low of Rs.41 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about its financial health and valuation metrics.

Roopa Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 July 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Roopa Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 July 2025. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a fresh 52-week low of Rs 41.34, marking a significant decline amid a three-day losing streak that has seen the stock shed nearly 11% of its value. This downturn contrasts sharply with broader market trends and highlights ongoing pressures on the company’s share price.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs 41.34, marking a significant decline amid broader market weakness. The stock has experienced a notable downward trajectory over recent sessions, reflecting ongoing pressures within the company’s financial and market performance.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs 41.34, marking a significant decline amid broader market weakness and sector underperformance.

Roopa Industries has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The pharmaceutical and biotechnology company’s recent assessment highlights a combination of subdued fundamental strength and bearish market signals, contributing to a cautious stance among investors.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.42, reflecting a significant decline amid a day marked by high volatility and underperformance relative to its sector peers.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.43 today, marking a significant price level amid a day of high volatility and mixed intraday movements.

Roopa Industries, a microcap in the Pharmaceuticals & Biotechnology sector, reported a challenging financial quarter ending September 2025, with declines in key metrics such as operating cash flow and return on capital employed. Despite significant long-term growth, recent performance issues underscore the need for operational improvements.

Roopa Industries, a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low of Rs. 45.11 amid ongoing market challenges. The stock has underperformed its sector and shows a significant decline over the past year, reflecting weak financial metrics and a persistent downward trend.

Roopa Industries, a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low of Rs. 45.11, following consecutive losses. The stock is trading below key moving averages and has seen a significant decline over the past year, indicating ongoing challenges for the company.

Roopa Industries has hit a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and is trading below key moving averages. Despite a profit increase, its financial metrics indicate weak long-term strength, with a low ROCE and high Debt to EBITDA ratio.